Compare
NeoGenomics Inc vs Medpace Holdings, Inc. vs UL Solutions Inc. vs NRC Health
| Latest fiscal year | NeoGenomics Inc NEO | Medpace Holdings, Inc. MEDP | UL Solutions Inc. ULS | NRC Health NRC |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $727.33M | $2.53B | $3.05B | $137.39M |
| Revenue growth (YoY) | +10.1% | +20.0% | +6.4% | -4.0% |
| Gross margin | 43.2% | n/a | 49.5% (computed) | n/a |
| Operating margin | -15.9% | 21.1% | 17.1% | 16.4% |
| Net margin | -14.9% | 17.8% | 10.6% | 8.4% |
| Net income | -$108.03M | $451.12M | $325.00M | $11.60M |
| EPS (Diluted) | n/a | $15.28 | $1.60 | $50.00 |
| Operating cash flow | $5.23M | $713.22M | $600.00M | $26.45M |
| Free cash flow | -$21.78M | $681.87M | $403.00M | $15.74M |
| Cash & equivalents | $159.62M | $497.05M | $295.00M | $4.14M |
| Total assets | $1.36B | $1.98B | $2.92B | $134.88M |
| Total liabilities | $523.27M | $1.52B | $1.63B | $120.89M |
| Shareholders' equity | $836.56M | $459.07M | $1.29B | $13.99M |
| Return on year-end equity | -12.9% | 98.3% | 25.1% | 82.9% |
| Shares outstanding | 128.15M | 28.37M | 201.03M | 22.64M |
Revenue, most recent five fiscal years
| Fiscal year | NeoGenomics Inc | Medpace Holdings, Inc. | UL Solutions Inc. | NRC Health |
|---|---|---|---|---|
| Latest | $727.33M Ended 2025-12-31 | $2.53B Ended 2025-12-31 | $3.05B Ended 2025-12-31 | $137.39M Ended 2025-12-31 |
| 1 year earlier | $660.57M Ended 2024-12-31 | $2.11B Ended 2024-12-31 | $2.87B Ended 2024-12-31 | $143.06M Ended 2024-12-31 |
| 2 years earlier | $591.64M Ended 2023-12-31 | $1.89B Ended 2023-12-31 | $2.68B Ended 2023-12-31 | $148.58M Ended 2023-12-31 |
| 3 years earlier | $509.73M Ended 2022-12-31 | $1.46B Ended 2022-12-31 | $2.52B Ended 2022-12-31 | $151.57M Ended 2022-12-31 |
| 4 years earlier | $484.33M Ended 2021-12-31 | $1.14B Ended 2021-12-31 | n/a | $147.95M Ended 2021-12-31 |